Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,503.20
(
0.00%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
108.60
(
0.32%
)
Bitcoin
67,679.99
(
2.61%
)
News Focus
News Focus
Post# of 257302
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122817
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 223815

Friday, 03/01/2019 8:04:09 PM

Friday, March 01, 2019 8:04:09 PM

Post# of 257302
TNXP—Now we know the impetus for the buyback authorization:

https://globenewswire.com/news-release/2019/03/01/1745581/0/en/Tonix-Pharmaceuticals-Provides-Update-on-Tonmya-for-the-Treatment-of-Posttraumatic-Stress-Disorder.html

The U.S. Food and Drug Administration (FDA) notified the Company that the Breakthrough Therapy designation (BTD) granted for Tonmya for PTSD in December 2016 has been rescinded because interim analysis data on Tonmya from the HONOR study do not support the continuation of the BTD.

This PR came out 90 minutes after the other one. LOL

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today